US 9,809,808 B2
Antimicrobial agents
Yves Briers, Rohr AG (CH); Rob Lavigne, Ekeren (BE); and Guido Volckaert, Holsbeek (BE)
Assigned to KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D, Leuven (BE)
Appl. No. 13/61,053
Filed by Yves Briers, Rohr AG (CH); Rob Lavigne, Ekeren (BE); and Guido Volckaert, Holsbeek (BE)
PCT Filed Aug. 25, 2009, PCT No. PCT/EP2009/060947
§ 371(c)(1), (2), (4) Date May 31, 2011,
PCT Pub. No. WO2010/023207, PCT Pub. Date Mar. 4, 2010.
Claims priority of application No. 0815484.1 (GB), filed on Aug. 26, 2008.
Prior Publication US 2011/0243915 A1, Oct. 6, 2011
Int. Cl. C12N 9/52 (2006.01); C12N 9/36 (2006.01); A61K 38/00 (2006.01)
CPC C12N 9/2462 (2013.01) [C12N 9/52 (2013.01); A61K 38/00 (2013.01)] 15 Claims
 
1. An endolysin variant comprising an bacteriophage peptidoglycan hydrolase to which a cationic peptide stretch with LPS disrupting activity is fused, wherein said cationic peptide stretch consists of 5 to 50 amino acid residues and wherein at least 70% of the amino acid residues comprised in said peptide stretch are arginine and/or lysine and 0% to 30% are serine and/or glycine, and wherein said endolysin variant exhibits (i) the activity of degrading a cell wall of Gram-negative bacteria and (ii) LPS disrupting activity.